Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice

References

• Global Oncology Trend Report. A review of 2015 and outlook to 2020. IMS Institute for Healthcare Informatics; 2016 June.
   Google Scholar
• Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12(7):570–577.
   PubMed Web of Science ®Google Scholar
• O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87(9):933–937.
   PubMed Web of Science ®Google Scholar
• Ribed A, Escudero-Vilaplana V, Romero-Jimenez RM, et al. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents. Expert Opin Drug Saf. 2016;15(4):427–435.
   PubMed Web of Science ®Google Scholar
• Clairet AL, Boiteux-Jurain M, Curtit E, et al. Interactions between phytotherapy and oral anticancer agents: prospective study and literature review. Med Oncol. 2019;36(5):45.
   PubMed Web of Science ®Google Scholar
• Collado-Borrell R, Escudero-Vilaplana V, Romero-Jiménez R, et al. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account. J Cancer Res Clin Oncol. 2016;142(11):2319–2330.
   PubMed Web of Science ®Google Scholar
• Bulsink A, Imholz AL, Brouwers JR, et al. Characteristics of potential drug-related problems among oncology patients. Int J Clin Pharm. 2013;35(3):401–407.
   PubMed Web of Science ®Google Scholar
• Escudero-Vilaplana V, Ribed A, Romero-Jimenez RM, et al. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents. Eur J Cancer Care (Engl). 2017;26(3):e12463.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RW, van Gelder T, Mathijssen RH, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315–326.
   PubMed Web of Science ®Google Scholar
• Jermini M, Dubois J, Rodondi PY, et al. Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Sci Rep. 2019;9(1):5078.
   PubMedGoogle Scholar
• Sharma M, Vadhariya A, Chikermane S, et al. Clinical outcomes associated with drug-drug interactions of oral chemotherapeutic agents: a comprehensive evidence-based literature review. Drugs Aging. 2019;36(4):341–354.
   PubMed Web of Science ®Google Scholar
• ATC/DDD Index 2019. WHO collaborating centre for drug statistics methodology. [ cited 2019 July]. Available from: https://www.whocc.no/atc_ddd_index/
   Google Scholar
• Lexicomp. Drug interactions. Wolters kluwer clinical drug information. Hudson, Ohio: Lexi-Comp, Inc; [ cited 2019 June]. Available from: www.lexi.com/online
   Google Scholar
• Memorial Sloan Kettering Cancer Center’s About Herbs database. Memorial sloan kettering cancer center. New York (NY); 2018 [cited 2019 June]. Available from: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/search
   Google Scholar
• Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546–558.
   PubMed Web of Science ®Google Scholar
• Ko Y, Tan SL, Chan A, et al. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther. 2012;34(8):1696–1704.
   PubMed Web of Science ®Google Scholar
• Récoché I, Rousseau V, Bourrel R, et al. Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016;95(40):e5076.
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20(12):1907–1912.
   PubMed Web of Science ®Google Scholar
• Alkan A, Yaşar A, Karc E, et al. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support Care Cancer. 2017;25(1):229–236.
   PubMed Web of Science ®Google Scholar
• Díaz-Carrasco MS, Almanchel-Rivadeneyra M, Tomás-Luiz A, et al. Observational study of drug-drug interactions in oncological inpatients. Farm Hosp. 2018;42(1):10–15.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RW, Brundel DH, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancerdrugs. Br J Cancer. 2013;108(5):1071–1078.
   PubMed Web of Science ®Google Scholar
• Keller KL, Franquiz MJ, Duffy AP, et al. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2018;24(2):110–115.
   PubMed Web of Science ®Google Scholar
• Riu-Viladoms G, Carcelero San Martín E, Martín-Conde MT, et al. Drug interactions with oral antineoplastic drugs: the role of the pharmacist. Eur J Cancer Care (Engl). 2019;28(1):e12944.
   PubMed Web of Science ®Google Scholar
• Solomon JM, Ajewole VB, Schneider AM, et al. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. J Oncol Pharm Pract. 2019;25(7):1564–1569.
   PubMed Web of Science ®Google Scholar
• Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, et al. CML Spanish Group (GELMC). Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem? Ann Hematol. 2018;97(11):2089–2098.
   PubMed Web of Science ®Google Scholar
• Carcelero E, Anglada H, Tuset M, et al. Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opin Drug Saf. 2013;12(3):403–420.
   PubMed Web of Science ®Google Scholar
• Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract. 2017;13(7):e613–e622.
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.
   PubMedGoogle Scholar
• Bayraktar-Ekincioglu A, Demirkan K, Keskin B, et al. Potential drug interactions and side effects in an outpatient oncology clinic: a retrospective descriptive study. Eur J Hosp Pharm. 2014;21:2016–2221.
   Google Scholar
• Xtandi. European public assessment reports. London: European Medicines Agency; [ cited 2019 Nov]. Available from: https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_en.pdf
   Google Scholar
• Benoist GE, van Oort IM, Smeenk S, et al. Drug-drug interactions potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122–129.
   PubMed Web of Science ®Google Scholar
• Neuss MN, Gilmore TR, Belderson KM, et al. 2016 updated American society of clinical oncology/oncology nursing society chemotherapy administration safety standards, including standards for pediatric oncology. J Oncol Pract. 2016;12(12):1262–1271.
   PubMed Web of Science ®Google Scholar
• Parsad S, Ratain MJ. Drug-drug interactions with oral antineoplastic agents. JAMA Oncol. 2017;3(6):736–738.
   PubMed Web of Science ®Google Scholar